Table 2.
Features of 13 SARS-CoV-2 neutralizing antibodies
| mAb ID | Binding specificity* | Neutralization WT IC100 (ng:mL)* | Neutralization D614G IC100 (ng:mL)* | Neutralization PT188-EM IC100 (ng:mL) |
| J08 | S1-RBD | 3.9 | 7.8 | 22.1 |
| I14 | S1-RBD | 11.0 | 19.7 | 176.8 |
| F05 | S1-RBD | 3.9 | 4.9 | Not neutralizing |
| G12 | S1-RBD | 39.4 | 39.4 | Not neutralizing |
| C14 | S1-RBD | 157.5 | 78.7 | 88.4 |
| B07 | S1-RBD | 99.2 | 49.6 | 250.0 |
| I21 | S1 | 99.2 | 198.4 | Not neutralizing |
| J13 | S1 | 396.8 | 500.0 | Not neutralizing |
| D14 | S1 | 396.8 | 250.0 | Not neutralizing |
| H20 | S protein | 492.2 | 310.0 | Not neutralizing |
| I15 | S protein | 310.0 | 155.0 | Not neutralizing |
| F10 | S protein | 155.0 | 195.3 | Not neutralizing |
| F20 | S protein | 246.1 | 155.0 | Not neutralizing |
The table shows the binding and neutralization profile of 13 previously identified SARS-CoV-2 nAbs.
*
Column refers to previously published data (1).